anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A method for producing a liquid pharmaceutical preparation which contains a complex consisting of DOTA and gadolinium and a base such as L-lysine or meglumine, includes the following steps: a) An aqueous solution containing free DOTA, free gadolinium and a base such as L-lysine or meglumine is produced. b) The yield of free DOTA and free gadolinium is determined in the solution obtained according to step a). c) Free gadolinium and/or free DOTA is added in order to adjust a stoichiometric excess of free DOTA in the solution. d) The complexation is executed at an increased temperature. e) Additional base such as L-lysine or meglumine is added in order to adjust the pH value. f) The final volume of the preparation is adjusted.
Systems and methods may use a mobile device communicatively coupled to a wearable device to present an exercise to a user. The systems and methods may modify a therapy calendar, for example, based on information determined from the exercise (e.g., repetitions completed, a duration completed, video, etc.), feedback from the user, or the like. A method may include receiving a control command from a wearable device communicatively coupled to a mobile device, the control command causing an action to be taken by the mobile device related to the exercise. The therapy calendar may be automatically modified, such as in response to determining a number of repetitions or a duration of an exercise. The modified therapy calendar may be presented on a user interface, such as on a display of the wearable device or the mobile device.
A total of 30 knee OA patients and 30 age/sex-matched healthy volunteers were included in the exercise and control groups. Exercises were performed twice a week under supervision and once a week as home program for eight weeks. Before and after exercise treatment, peripheral venous blood samples were taken from both groups. miRNA-146a, miRNA-155, miRNA-221-3p and miRNA-145 gene expressions were studied with the Real-time PCR method. miRNA-146a, miRNA-155, and miRNA-221-3p, miRNA-145 gene expressions were studied with the Real-time PCR method. The pain was evaluated with the Numeric Rating Scale (NRS), functional status with Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), depression level with the Beck Depression Inventory (BDI), and quality of life with Short Form-36 (SF-36).
PROBLEM TO BE SOLVED: To provide stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11.SOLUTION: The present invention relates to an isolated protein comprising a stabilized activin IIB receptor polypeptide. The present invention also relates to an isolated nucleic acid molecule comprising a polynucleotide encoding the polypeptide. The present invention also relates to a recombinant vector comprising the nucleic acid molecule. The present invention also relates to a host cell comprising the recombinant vector. The present invention also relates to a method of producing an svActRIIB protein comprising the steps of culturing the host cell under conditions promoting the expression of the svActRIIB protein, and recovering the protein. The present invention also relates to a pharmaceutical composition comprising an effective amount of the protein in admixture with a pharmaceutically acceptable carrier.
The invention discloses a Chinese medicine soft capsule for treating upper respiratory infection. The Chinese medicine soft capsule is a solid preparation prepared by subjecting a radix scutellariae extract, a fructus gardeniae extract and pharmaceutic adjuvants in a proper proportion to a proper preparation process. The Chinese medicine soft capsule has the efficacies of resisting virus, killing bacteria, diminishing inflammation, relieving pain, and clearing away heat, and can be used for effectively treating the upper respiratory infection; and compared with a conventional preparation, the Chinese medicine soft capsule has the characteristics of good taste, rapid absorption, fast action, strong efficacy, convenience for taking, good adaptability and the like. The invention also discloses a preparation method of the Chinese medicine soft capsule. The invention further comprises a quality detection method of the Chinese medicine soft capsule. The quality detection method comprises the three parts of verification, inspection and content measurement. According to the quality detection method disclosed by the invention, the quality control standard of the traditional Chinese medicine soft capsule is improved, and therefore the clinical curative effect of the Chinese medicine soft capsule can be fully ensured.
Patients eat a special low-calorie diet during 3 days prior to chemotherapy, during the 12 weeks of chemotherapy, and 2 days after chemotherapy. Patients are provided with all meals and all food to be consumed and maintain a diary of the food consumed and appropriate amounts.
Eligible subjects will receive a single dose of 100 micrograms (mcg) nemiralisib on Day 1 in Period 1. Subjects will also receive a single dose of 200 milligrams (mg) itraconazole in the morning from Day 1 to Day 10 and single dose of 100 mcg nemiralisib on Day 5, one hour after the dose of itraconazole in Period 2. There will be a washout of at least 14 days between the administration of nemiralisib in Period 1 and Period 2.
Abdominal hemorrhage is an important clinical disease that can be life-threatening in severe cases. Therefore, timely detection and treatment of abdominal hemorrhage is crucial for the health and safety of patients. Magnetic induction tomography is a non-invasive, nonradioactive, and non-contact electromagnetic imaging technology with potential application value for disease screening and continuous monitoring. In this paper, a simulation model of electrical impedance distribution close to the real human abdominal tissue was constructed, and based on this model, the magnetic induction tomography simulation method of internal bleeding was studied by the finite element numerical method, and the comparison was verified by phantom experiments. The eddy current density distribution inside the abdominal tissue and the magnetic induction phase data at the tissue boundary are solved, and sensitivity analysis of phase differences caused by changes in the radius and position of bleeding volume was conducted, and three sensitivity indicators were proposed. Both the simulation and phantom experiment show that when there are six types of tissues with different conductivity in the abdomen, the radius of bleeding increases from 10 to 30 mm, and the radius phase difference sensitivity index Ar increases approximately linearly monotonically. Its radius transformation sensitivity Kr is 3.0961 × 10-5°/cm. When the position of the bleeding volume changes, the sensitivity index Ax of the x-axis displacement phase difference shows a quasilinear monotonic decrease, and the x-axis displacement sensitivity Kx is -6.3744 × 10-6°/cm. The y-axis displacement phase difference sensitivity Ay index shows a quasilinear relationship and monotonically increases, with a y-axis displacement sensitivity Ky of 5.2870 × 10-4°/cm. The results indicate that the phase difference sensitivity before and after the occurrence of bleeding can be used as a quantitative monitoring indicator to monitor the occurrence and trend of intra-abdominal hemorrhage, laying the foundation for the preliminary screening and continuous monitoring of abdominal hemorrhage diseases using magnetic induction imaging.
TBI with initial Glasgow Coma Scale (GCS) ≤ 8 and AISextrahead score ≤3. Oropharyngeal and rectal swabs will be performed for each patient within the first 24 hours after ICU admission (day 0), then 48 hours (day 2) and 7 days (day 7) after ICU admission and weekly thereafter until ICU discharge.
BACKGROUND: Full thickness defects of the ala, soft triangle, and nasal tip involving the nasal lining have traditionally been repaired with the three-stage folded paramedian forehead flap (FPFF), with a cartilage graft for support. For similar defects, the authors utilize the two-stage FPFF without cartilaginous support which provides reproducible functional and aesthetic results.  Objective: To describe the authors' experience with the two-stage FPFF, including outcomes, complications, and design modifications to enhance functional and aesthetic success.  Methods: An IRB-approved retrospective database review of FPFF was performed at two sites. Using postoperative photographs, outcomes were assessed by blinded non-investigator dermatologist raters using a modified observer scar assessment scale.
RESULTS: Thirty-five patients were reconstructed using the two-stage FPFF without cartilage grafts. Subjective assessment of scar vascularity, pigment, relief, and thickness by 3 independent reviewers yielded an overall cosmesis score of 8.4±1.9 (out of 40).
CONCLUSION: The two-stage FPFF without cartilage grafts is a reliable, cosmetically elegant repair that can provide optimal functional and aesthetic results for complex unilateral distal nose defects.J Drugs Dermatol. 2024;23(4): doi:10.36849/JDD.7358.
Control group = standard of Care regimen: 1000ml = 1000 kCal TPN postop from day 1 until day 7. Oral feeds are started from day 5 onwards if no arguments for clinical leak (cervical anastomosis) or barium swallow is normal. Oral intake consists of regular post gastrectomy diet (building up from fluids over semi-solids to solids) with eventually added high nitrogen energy drinks.
About 50 people will be asked to take part in this study at this location. This will include participants with early-onset AD and their parents and siblings. Participants will be asked to: Sign this consent form or have a Legally Authorized Representative sign and provide the participant' health history. The study staff will review the participant's medical history and test results to see if the participant can be part of this study, The study staff will need to know any over-the-counter or prescription drugs, vitamins, or herbs taken by the participant. The study staff will discuss what is required to be part of this study. Participants cannot take part in this study if they have: Family history of early or late-onset Alzheimer's disease, Uncontrolled concurrent illness including psychiatric illness or situations that would limit compliance with the study requirements or the ability to willingly give written or verbal consent. If the participant agrees to take part in this study, one 8mL blood sample (about 2 teaspoons) will be collected from them. If the participant is receiving a clinically indicated blood draw, the blood collections for this study will occur at the same time. Participants may be required to have a research-specific blood draw if they are not scheduled for a blood draw during a regularly scheduled visit.
Hemophilic arthropathy (HA) is a condition caused by recurrent intra-articular bleeding in patients with hemophilia. Pro-inflammatory cytokines play a crucial role in the pathogenesis of HA. Our previous research demonstrated that a novel compound, piperazino-enaminone (JODI), effectively inhibited pro-inflammatory cytokines, including IL-6, MCP-1, MIP-1α, and MIP-1β, in a mouse model of hemarthrosis. This study aims to enhance the anti-inflammatory effect of JODI by employing nanoparticle delivery systems, which could potentially improve its poor water solubility. Here, we developed liposomes modified with polyethylene glycol (PEG) for the delivery of JODI (JODI-LIP), and found that JODI-LIP exhibited uniform size, morphology, good stability and in vitro release degree. JODI-LIP mitigated cytotoxicity of JODI, and significantly suppressed the production of pro-inflammatory cytokines (TNF-α and IL-1β) and nitric oxide (NO) release in RAW 264.7 cells stimulated by lipopolysaccharide (LPS), as well as the proliferation of human fibroblast-like synovial (HFLS) cells. In a murine model of HA, JODI-LIP demonstrated superior efficacy in ameliorating joint swelling and synovitis, compared to JODI. Importantly, JODI-LIP markedly reduced pro-inflammatory cytokines (TNF-α, IFN-γ, IL-33, and MCP-1) in injured joints. No hepatic or hematological toxicity was observed in mice treated with JODI-LIP. In summary, our results suggest that JODI-LIP holds promise as a therapeutic intervention for HA by attenuating pro-inflammatory cytokine levels.
PURPOSE: To provide a medicinal compsn. for asthma treatment which consists of (S)-α-fluoromethyl histidine or its salt or ester as an effective component or is formed by combining the same with another anti-asthmatic agents and prevents or suppresses the basic progression of the asthma. CONSTITUTION: This asthma treatment medicinal compsn. consists of the (S)-α- fluoromethylhistidine of the formula (R is H, a medicinally usable ester forming group) or its salt or ester as the effective component. The compd. into which 10 mg to 2 g the component described above as the effective component is more preferable. The compsn. is recommended to be used in combination with the antiasthmatic agents selected from a phosphodiesterase inhibitor, β2 working medicine, steroid agent, mediator free suppressor, LTD4 antagonist and PAF antagonist together with the effective amt. of the (S)-α-fluoromethylhistidine of the formula, its salt and its ester.
Epidemiologic, laboratory, and clinical reports all suggest that vitamin D3 (cholecalciferol) plays a desirable role in the prevention and prognosis of prostate and other cancers. Prostate cancer cells possess both of the enzymes required to convert vitamin D to the active paracrine hormone, calcitriol. However, the dose-response relationship between serum levels of calcidiol (vitamin D status) and prostate tissue levels of calcidiol and calcitriol is yet to be defined. As a neoadjuvant, prior to radical prostatectomy (for 4-6 wk) vitamin D3 \[400 IU (control group), 10,000 IU or 40,000 IU/day\] will be given to 90 men randomized, double-blinded, 30 per dose. Immediately after surgery, the pathologist will obtain a few grams of prostate tissue, some of which will be used to assay calcidiol and calcitriol within prostate. From the embedded prostate, we will prepare immunohistochemically stained sections to characterize cellular responses and morphological changes. Our hypothesis is that vitamin D will increase intraprostate calcitriol concentration and thereby lower cellular proliferation (as judged by the markers MIB-1 and p27) in zones of Gleason pattern 3 prostate cancer and in pre-cancerous (PIN) lesions. We expect that our results will provide surrogate outcomes to justify larger trials of vitamin D for treatment of prostate cancer. This research has the potential to: 1. Provide direct evidence at the cellular level using clinical samples that vitamin D lowers cellular proliferation in prostate cancer, 2. Provide guidance about the serum calcidiol concentrations (and thereby vitamin D doses) that should be targeted for such studies, and 3. Eventually support other research directed at vitamin D as a primary prevention strategy.
Gastroesophageal reflux disease (GERD) has been linked to many disorders and can be diagnosed through a variety of modalities utilizing 24 hour ambulatory pH monitoring which can register the duration, pattern and symptom correlation of distal esophageal acid exposure. This can be accomplished via a catheter probe connected from outside the body and placed through a nostril, advanced past the hypopharynx and down into the distal esophagus. Or, a small pH detector temporarily implanted in the distal esophagus during endoscopy can record reflux events. However, despite available technologies, there has long been a deficiency in detecting extra-esophageal reflux in the upper esophagus/ hypopharynx. This is of interest for gastroenterologists, otolaryngologists, and pulmonologists in the evaluation of extra-esophageal reflux as a potential culprit for asthma, chronic cough, laryngitis, globus, and non-cardiac chest pain. Until now, there has not been a device sensitive enough for accurately detecting extra-esophageal reflux (EERD) and clinicians have relied upon subjective response to empiric treatment with acid reducing medications to determine whether acid reflux was at the root of the symptoms. There are currently no well designed published studies with this device to assess its role in this group of difficult to treat patients.
Parkinson's disease is caused by the preferential loss of substantia nigra dopamine neurons. A Parkin Interacting Substrate, PARIS (ZNF746) is identified. The levels of PARIS are regulated by the ubiquitin proteasome system via binding to and ubiquitination by the E3 ubiquitin ligase, parkin. PARIS is a KRAB and zinc finger protein that accumulates in models of parkin inactivation and in human brain Parkinson's disease patients. PARIS represses the expression of the transcriptional co-activator, PGC-1α and the PGC-1α target gene, NRF-1 by binding to insulin response sequences in the PGC-1α promoter. Conditional knockout of parkin in adult animals leads to progressive loss of dopamine (DA) neurons that is PARIS dependent. Overexpression of PARIS causes selective loss of DA neurons in the substantia nigra, which is reversed by either parkin or PGC-1α co-expression. The identification of PARIS provides a molecular mechanism for neurodegeneration due to parkin inactivation.
Patients receive rituximab IV or rituximab and hyaluronidase human SC, cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1, and prednisone PO on days 1-5 of cycle 1. Cycles repeat every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use amiodarone hydrochloride tablets for a condition for which it was not prescribed. Do not share amiodarone hydrochloride tablets with other people, even if they have the same symptoms that you have. It may harm them.

If you have any questions or concerns about amiodarone hydrochloride tablets, ask your doctor or healthcare provider. This Medication Guide summarizes the most important information about amiodarone hydrochloride tablets. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about amiodarone hydrochloride tablets that was written for healthcare professionals. Please address medical inquiries to, (MedicalAffairs@zydususa.com) Tel.: 1-877-993-8779.
A preparation for nasal-nasopharyngeal treatment, the preparation comprising: a carrier, between 0.8% and 59% by weight/ volume of a medicament selected from the group consisting of sugar monomers of the aldohexose series of carbohydrates; and a pharmaceutically effective amount of an antimicrobial preservative is provided. The sugar monomer of the aldohexose is preferably D-mannose. The carrier may be water. The antimicrobial preservative may be selected from one or more of the group consisting of: benzalkonium chloride, phenylcarbinol, EDTA, benzyl alcohol, 2-phneylethanol, 3-phenylpropanol, cetrimide, 3-cresol, chlorhexidine and organo mercurials. A process of manufacturing said preparation is provided. Said preparation for use in a method of treatment of a patient suffering from nasopharyngeal congestion; hypersensitivity, inflammation; irritation associated upper respiratory infections; hay fever; post-nasal drip; sinusitis or otitis media is provided.
Effective acute pain control is mandatory after injury. Opioids continue to be a pillar acute pain management of strategies despite not being as effective as some nonnarcotic alternatives. An acute pain management strategy after trauma should be thoughtful, effective, and responsible. A thoughtful approach includes managing a patient's expectations for acute pain control and ensuring that interventions purposefully and rationally affect the domain of pain that is uncontrolled. An effective pain management strategy includes a multimodal approach using acetaminophen, nonsteroidal anti-inflammatory drugs, and regional anesthesia. A responsible acute pain management approach includes knowing the relative strengths of the opioids prescribed and standardized approach to opioid prescribing at discharge to minimize diversion. Acute pain management is quite understudied, and future considerations include a reliable objective measurement of pain and the evaluation of nonmedication acute pain interventions.
Efficacy and safety data of EYLEA in ROP are derived from two studies (BUTTERFLEYE and FIREFLEYE/FIREFLEYE NEXT). BUTTERFLEYE was a 52-week study. FIREFLEYE included 24 weeks of treatment and follow-up. FIREFLEYE NEXT was an observational follow-up of FIREFLEYE through week 52.

Both BUTTERFLEYE and FIREFLEYE studies assessed the efficacy, safety and tolerability of EYLEA in randomized, 2-arm, open-label, parallel-group studies. The studies were conducted in pre-term infants with ROP providing a comparison between EYLEA treatment and laser photocoagulation therapy (laser). Each eligible eye received the assigned study treatment at baseline. Re-treatment and/or rescue treatment was administered if needed based on pre-specified criteria. Rescue treatment could potentially include the alternative treatment (EYLEA or laser). Re-treatment with aflibercept, if required, was administered up to 2 times in a particular eye, with at least 28 days between consecutive injections.

Eligible patients had a maximum gestational age at birth of 32 weeks or a maximum birth weight of 1500 g, had to weigh > 800 g on the day of treatment and had treatment-naïve ROP classified according to the International Classification for Retinopathy of Prematurity (IC-ROP 2005) in at least one eye with one of the following retinal findings:

  * ROP Zone 1 Stage 1+, 2+, 3 or 3+, or
  * ROP Zone II Stage 2+ or 3+, or
  * AP-ROP (aggressive posterior ROP)



The primary efficacy endpoint of each study was the proportion of patients with absence of active ROP and unfavorable structural outcomes (retinal detachment, macular dragging, macular fold, retrolental opacity) at week 52 of chronological age.

In BUTTERFLEYE, patients were randomized in a 3:1 ratio to receive 1 of 2 treatment regimens: 1) EYLEA 0.4 mg at baseline and if required, up to 2 additional injections and 2) laser photocoagulation in each eye at baseline and if required, retreatment. In FIREFLEYE, patients were randomized to the same two treatments, but in a 2:1 ratio. Rescue treatment was administered if required, per pre-specified criteria. In both studies, greater than 92% of all treated patients in the aflibercept group received bilateral injections during the study.

Results from week 52 of chronological age in the BUTTERFLEYE and FIREFLEYE/FIREFLEYE NEXT studies are shown in Table 12 below.

The proportion of patients without clinically significant reactivations of ROP who also did not develop unfavorable structural outcomes was higher in each arm of each study than would have been expected in infants who had not received treatment. Neither trial demonstrated superiority of one arm compared to the other arm. Neither trial demonstrated inferiority of one arm compared to the other arm.